Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend....
This is very beautiful opportunity. Historically, baxter always had heavy downtrend cycle of 65/70%. Now, Baxter is 68% down. RSI is at its lowest and it created amazing BULLISH DIVERGENCE (see 1M frame). I gave first target and second target, also according time period. I bought shares of Baxter. NO LEVERAGE. Ps. I advice you NEVER leverage. NYSE:BAX ...
Baxter has been obliterated on the back of Ozempic. This stocks is hitting multidecade support, in a very oversold condition on the larger time frames. You also have a Monthly RSI divergence occurring which could help the technical bounce scenario .
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled...
Target horizon - 2 months. Target - 84 USD. Profit/risk ratio - 3.43 The price is approaching the upper boundary of the downtrend, and if it breaks it is likely to go to the support line around 85 USD. Baxter International is an American medical device manufacturer specializing in high-tech dialysis machines and other medical devices and supplies. Thousands of...
BAXTER is in an uptrend on the weekly chart. The price is making higher lows and higher highs. In the short term it has broken a bearish channel with a wide-ranging weekly candlestick that indicates ample volume. We are looking for a little more than one to one in our risk/reward ratio. --------------------------------------------------------- BAXTER está en...
Baxter International couldn't break the pivot resistance and pulling back